Halozyme Therapeutics, Inc. Stock News

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Helen Torley - President, CEO & Director Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Awesome. Thank you very much for joining us today.

Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.

SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences.  Details on the Company's participation are as follows: E...

Biotech stock Halozyme Therapeutics rallies to an all-time high on Thursday. Shares are in a buy zone above a buy point of 70.51.

Bank of America reiterated its buy rating on Palantir with a price target of $180.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO Tram Bui - Head of Investor Relations & Corporate Communications Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Brendan Mychal Smith - TD Cowen, Research Divisi...

Halozyme (HALO) Q2 EPS Jumps 69%

Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.54 1 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million, Representing YOY G...